Quantcast

Latest Flibanserin Stories

2010-06-18 15:32:00

RIDGEFIELD, Conn., June 18 /PRNewswire/ -- The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA). The FDA will consider the committee's advice as part of its final assessment of the NDA. The committee recognized the...

fb905fc98aa63cd7e7d7349aa679b00b1
2010-06-17 06:35:00

The drug industry's latest attempt to find a female equivalent to Viagra fell short in two separate studies, according to federal regulators on Wednesday. The Food and Drug Administration is considering Boehringer Ingelheim's drug flibanserin for pre-menopausal women who experienced a lack in sexual desire, a market that drug makers have been targeting for years since the epic success of Viagra for men. The hunt for a female version of Viagra has proved elusive though, with many drugs...

2010-05-19 11:30:46

New analyses from pivotal Phase III flibanserin trials presented May 18 Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo. Flibanserin is an investigational compound being developed by Boehringer Ingelheim Pharmaceuticals, Inc. for the treatment of HSDD...

2010-05-18 17:30:00

RIDGEFIELD, Conn., May 18 /PRNewswire/ -- Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo. Flibanserin is an investigational compound being developed by Boehringer Ingelheim Pharmaceuticals, Inc. for the treatment of HSDD in pre-menopausal women....

fa84e3378ebd3659aacdb172e36676891
2010-02-27 06:55:00

Drugmakers have waited to find an equivalent to Viagra for women ever sense Pfizer introduced the blue pill to the pharmaceutical market. Reuters reports that Germany's Boehringer Ingelheim is ahead of the race to find a similar pill for a female libido, which could excite passions of a different kind among some women's health experts. Boehringer funded a survey that showed the emotional impact and distress caused by low sexual desire. However, critics say it is evidence of the firm's...

2009-11-19 08:00:00

MUNSTER, Germany, November 19 /PRNewswire/ -- MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a serious burden to some of those affected, since it may be disabling for the patients and...

2009-11-16 16:00:49

Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin is an investigational compound being developed by Boehringer Ingelheim for the treatment of HSDD in pre-menopausal women. HSDD is a decrease or lack of sexual desire that causes distress for the patient, may put a...

ec8c1a8f8062c87e8be3ccb89baacf171
2009-11-16 13:55:00

A medicine manufactured by German company Boehringer Ingelheim has been shown to increase a woman's sex drive, making the group the first to launch a non-hormonal treatment for women with decreased libido. The pill is made with flibanserin and encourages sexual cravings and increases the amount of "satisfying sexual events" in women with unusually low libido, Boehringer announced on Monday. The results of four investigations of 2,000 pre-menopausal women plagued with Hypoactive Sexual Desire...

2009-11-16 10:00:00

It is estimated that 1 in 10 American women suffer from decreased sexual desire that causes interpersonal distress-a condition that could be Hypoactive Sexual Desire Disorder (HSDD). HSDD is defined as a decrease in or absence of thoughts and desires for any form of sexual activity. It can affect women of all ages, at any stage of life and may put a strain on relationships. There is currently no FDA-approved treatment for this condition. New research on the first compound in a...

2009-11-16 07:00:00

RIDGEFIELD, Conn., Nov. 16 /PRNewswire/ -- Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin is an investigational compound being developed by Boehringer Ingelheim for the treatment of HSDD in pre-menopausal women. HSDD is a decrease or lack of sexual desire that...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related